Plain-English translation of NCT07374692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new technology called SmartMatch, an artificial intelligence system that analyzes your tumor tissue to predict which existing FDA-approved drugs might be most effective for your specific brain cancer. Researchers will collect a small sample of your tumor during a planned biopsy or surgery and use SmartMatch to run tests on it. The goal is to see if this tool can quickly identify personalized treatment options for patients with advanced brain tumors.
Brain tumors are rare and difficult to treat, especially when they come back after initial treatment. Standard drug development takes many years, but this medication uses artificial intelligence to repurpose drugs that already exist, potentially finding better treatment options much faster for patients like you.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have a small sample of your tumor collected during your scheduled brain biopsy or surgery at NIH (this would happen anyway as part of your normal care). Researchers will then send your tissue sample to the SmartMatch laboratory, where artificial intelligence will analyze it and predict which drugs might work best for your tumor. The study aims to provide these personalized drug recommendations within 21 days. You won't need to take any experimental drugs through this study — it's focused on testing how quickly and accurately the tool can generate these personalized recommendations.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States